Maverick Capital Ltd. Boosts Holdings in Illumina, Inc. $ILMN

Key Points

• Maverick Capital Ltd. increased its shares in Illumina, Inc. by 212.3% during the first quarter, now holding a total of 9,351 shares valued at approximately $742,000.
• Recent analyst ratings for Illumina present a mixed outlook, with six analysts recommending a Buy, eleven a Hold, and two a Sell, while the average target price stands at $123.17.
• Illumina's latest quarterly results showed earnings per share of $1.19, outperforming expectations, despite a revenue decline of 4.8% year-over-year.

Maverick Capital Ltd. raised its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 212.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,351 shares of the life sciences company's stock after acquiring an additional 6,357 shares during the quarter. Maverick Capital Ltd.'s holdings in Illumina were worth $742,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ILMN. Rakuten Securities Inc. lifted its holdings in Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after acquiring an additional 270 shares during the period. Center for Financial Planning Inc. acquired a new stake in Illumina in the first quarter valued at $33,000. Fourth Dimension Wealth LLC acquired a new stake in Illumina in the fourth quarter valued at $40,000. PFS Partners LLC lifted its holdings in Illumina by 400.0% in the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after acquiring an additional 400 shares during the period. Finally, Golden State Wealth Management LLC lifted its holdings in Illumina by 123.2% in the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after acquiring an additional 292 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Price Performance

Illumina stock traded up $1.25 during midday trading on Friday, reaching $98.93. 1,520,102 shares of the company were exchanged, compared to its average volume of 1,303,321. The company has a market capitalization of $15.21 billion, a price-to-earnings ratio of 12.52, a P/E/G ratio of 2.20 and a beta of 1.43. The firm's 50-day simple moving average is $99.63 and its 200-day simple moving average is $88.55. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm's quarterly revenue was down 4.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on ILMN shares. Wall Street Zen downgraded Illumina from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Piper Sandler cut their price target on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. JPMorgan Chase & Co. cut their price target on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Evercore ISI lifted their price target on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Finally, Canaccord Genuity Group lifted their price target on Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a research note on Friday, August 1st. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $123.06.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.